Results 21 to 30 of about 1,446 (139)

Conservation status of species used in the UK herbal medicine industry

open access: yesPLANTS, PEOPLE, PLANET, EarlyView.
Given the ongoing biodiversity crisis, sustainable use and management of medicinal plants is critical. We assessed the conservation status, threats and conservation actions of 298 species sold by UK suppliers to medical herbalists. We found that most species used are unevaluated, representing a gap in conservation knowledge, and of those with ...
Isabella Flowers   +2 more
wiley   +1 more source

Ashwagandha: Is It Safe? Part 1: A Regulatory Review

open access: yesPhytotherapy Research, EarlyView.
ABSTRACT Over the last decade, ashwagandha (Withania somnifera (L.) Dunal, AS) has been brought under increasing scrutiny by EU regulators regarding its safety for the use in food supplements, culminating in a recent recommendation for an Article 8 procedure according to Regulation (EC) No. 1925/2006 in the European Union (EU).
T. Brendler   +5 more
wiley   +1 more source

Biosystematics studies on medicinal plant Urginea indica Kunth. liliaceae - A review [PDF]

open access: yes, 2012
Indian squill, Urginea spp. is a very important and rare medicinal plant endemic to India, Africa and Meditteranian Regions. It has magical potential to heal many human diseases with cardiatonic, anticarcinomic, anti jaundice, anti dropsy, anti asthmatic,
Bijul Lakshman, A.   +2 more
core  

Pedunculoside Inhibits Hepatocellular Carcinoma Progression by Activating the MAPK Signaling Pathway Through Targeting and Suppressing CDK4

open access: yesPhytotherapy Research, EarlyView.
Pedunculoside targets and suppresses CDK4; consequently, it activates the MAPK pathway and inhibits hepatocellular carcinoma progression. ABSTRACT Hepatocellular carcinoma (HCC) remains a major challenge in cancer prevention and treatment, highlighting the urgent need for effective and low‐toxicity anti‐HCC therapies. Recently, CDK4‐targeted inhibitors
Yang Zhou   +9 more
wiley   +1 more source

Special Libraries, November 1952 [PDF]

open access: yes, 1952
Volume 43, Issue 9https://scholarworks.sjsu.edu/sla_sl_1952/1008/thumbnail ...
Special Libraries Association
core   +1 more source

Extrahepatic Gene Editing In Vivo Using Organic Solvent‐Free Lipid Nanoparticles

open access: yesSmall, EarlyView.
This article highlights a novel, organic solvent‐free lipid nanoparticle (LNP) formulation that avoids cholesterol, thereby reducing hepatic accumulation and immune activation. These BLNPs enable potent, flexible, and scalable gene delivery, supporting personalized medicine and diverse nucleic acid applications.
Michael Streiber   +14 more
wiley   +1 more source

Thai Traditional Medicine : An Overview and Overtones [PDF]

open access: yes, 2006
この論文は国立情報学研究所の学術雑誌公開支援事業により電子化されまし
Wongpanich Varima
core   +1 more source

Pseudorandomised controlled trial of a novel navel barrier solution versus 10% iodine to protect navel and ear tag sites of neonatal lambs

open access: yesVeterinary Record, EarlyView.
Abstract Background During lambing, 10% iodine is often used to protect neonatal navel and ear tag sites. The evidence for its effectiveness is sparse. Recently, a specific navel barrier solution (NBS) was developed. Here, an in vivo field trial compared the two treatments. Methods Ten farms reported data from 6840 lambs. The navel and ear tag sites of
Fiona M. Lovatt   +3 more
wiley   +1 more source

Five‐Grass‐Pollen Sublingual Immunotherapy Drops Are Efficacious and Well Tolerated in Adults: The RHAPSODY Phase III Trial

open access: yesAllergy, EarlyView.
The RHAPSODY multinational study investigated 26 months of continuous treatment with 5‐grass‐pollen sublingual SLIT drops in adults with moderate‐to‐severe grass‐pollen‐induced allergic rhinoconjunctivitis. The primary efficacy endpoint (the average daily total combined score) showed statistically significant differences in favour of the active ...
Alain Didier   +4 more
wiley   +1 more source

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
We conducted a nationwide, multicenter cohort study using a target trial emulation framework to compare baclofen and acamprosate in patients with compensated alcohol‐associated cirrhosis. After matching, baclofen initiation was associated with a higher 1‐year risk of major adverse liver outcomes, driven primarily by hepatic encephalopathy, particularly
Yee Hui Yeo   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy